Bellicum Pharmaceuticals Profile

USD 0.12  1.48%

Acquisition by Naeve Gregory S of 34125 shares of Bellicum Pharmaceuticals subject to Rule 16b-3

Bellicum Pharmaceuticals insider trading alert for grant of stock option (right to buy) by Naeve Gregory S, Chief Business Officer, on July 5, 2018. This event was filed by Bellicum Pharmaceuticals with SEC on 2018-07-05. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

Bellicum Pharmaceuticals Summary

Bellicum Pharmaceuticals (BLCM) is traded on BATS Exchange in USA. It is located in TEXAS U.S.A and employs 137 people. Bellicum Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Small-Cap' category with current market capitalization of 345.13 M. Bellicum Pharmaceuticals conducts business under Healthcare sector and is part of Biotechnology industry. This company has 42.87 M outstanding shares of which 2.84 M shares are currently shorted by private and institutional investors with about 4.59 trading days to cover. Bellicum Pharmace currently holds about 82.11 M in cash with (69.2 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.91.
Check Bellicum Pharmaceuticals Probability Of Bankruptcy

Ownership Allocation (%)

Target Price Odds Analysis

Odds Below 7.97HorizonTargetOdds Above 7.97
35.04%30 days 7.97 64.80%
Based on normal probability distribution, the odds of Bellicum Pharmaceuticals to move above current price in 30 days from now is about 64.8% (This Bellicum Pharmaceuticals probability density function shows the probability of Bellicum Pharmaceuticals Stock to fall within a particular range of prices over 30 days) .

Top Holders

Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Berson Corrado Investment Advisors LlcCommon Shares78.9 K582 K
Baker Bros Advisors LpCommon Shares4.2 M27.2 M
View Bellicum Pharmaceuticals Diagnostics

Selected Bellicum Pharmaceuticals Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Bellicum Pharmaceuticals Against Markets

Current Ratings

Bellicum Pharmaceuticals 30 Days Performance Scores
Risk Adjusted
Performance Score (0 to 100)
Chance of
Financial Distress (0 to 100%)
Equity ratings for Bellicum Pharmaceuticals are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Houston, Texas. Bellicum Pharmaceuticals operates under Biotechnology classification in USA and traded on NASDAQ General Markets. It employs 137 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Bellicum Pharmaceuticals SEC Filings
Bellicum Pharmaceuticals SEC Filings
Security & Exchange Commission EDGAR ReportsView All
NameBellicum Pharmaceuticals
President CEO, DirectorRichard FairView All
Thematic Classification
Currently Active Investing Idea
  Cancer Fighters
View All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Healthcare, Biotechnology
InstrumentUSA Stock View All
RegionNorth America
LocationTEXAS U.S.A
Business Address2130 West Holcombe Boulevard
ExchangeBATS Exchange
CIK Number0001358403
Phone832 384 1100
CurrencyUSD - US Dollar

Bellicum Pharmaceuticals Corporate Directors

Frank McGuyer Director
Stephen Davis Independent Director
Reid Huber Director, Ph.D
Check also Trending Equities. Please also try Content Syndication module to quickly integrate customizable finance content to your own investment portal.